从“浊毒”探析动脉粥样硬化病机及治疗
|
摘要
动脉粥样硬化是心脑血管疾病、周围血管疾病等重要发病机制,对人体健康有较大的影响以及危害。目前对动脉粥样硬化常以预防治疗和介入等治疗为主,复发率高,不易被患者接受。动脉粥样硬化致病具有广泛性、难治性、易损伤相应脏器,这与浊毒的致病特点极为相似,故我们认为动脉粥样硬化的病机为浊毒伏脉,并抓住浊毒特性探讨动脉粥样硬化的发病,为中医治疗动脉粥样硬化提高新思路。
Atherosclerosis is an important pathogenesis of cardiovascular and cerebrovascular diseases and peripheral vascular diseases,and has a great influence on human health. At present,atherosclerosis is often treated with prevention and intervention,and the recurrence rate is high,which is not easy to be accepted by patients. Atherosclerotic disease has universality,refractory,easy to damage the corresponding viscera. The muddy poisonous pathogenic characteristics are very similar,so we think that the pathogenesis of atherosclerosis is turbid and toxin,and seize the turbid and toxin characteristics to explore the pathogenesis of atherosclerosis,as the new ideas of TCM in the treatment of atherosclerosis.
Atherosclerosis is an important pathogenesis of cardiovascular and cerebrovascular diseases and peripheral vascular diseases,and has a great influence on human health. At present,atherosclerosis is often treated with prevention and intervention,and the recurrence rate is high,which is not easy to be accepted by patients. Atherosclerotic disease has universality,refractory,easy to damage the corresponding viscera. The muddy poisonous pathogenic characteristics are very similar,so we think that the pathogenesis of atherosclerosis is turbid and toxin,and seize the turbid and toxin characteristics to explore the pathogenesis of atherosclerosis,as the new ideas of TCM in the treatment of atherosclerosis.
引文
[1]吴文博.中医之“毒”新议[N].中国中医药报,2018-02-26(004).
[2]邢玉瑞.中医浊毒概念问题探讨[J].中医杂志,2017,58(14):1171-1174.
[3]徐伟超,贾蕊,李欣,等.浊毒病机理论探微[J].新中医,2015,47(9):1-3.
[4]赵雯红,肖颖,王文举,等.以人体微生态学诠释浊毒理论的内涵[J].中医杂志,2018,59(3):185-190.
[5]李永朝.动脉粥样硬化发生机制的研究进展[J].临床合理用药,2018,11(2):174-175.
[6]刘含嫣,霍清萍.单核细胞趋化蛋白-1与动脉粥样硬化及中医药防治[J].中西医结合心脑血管病杂志,2011,9(2):218-221.
[7]张志鑫,李彦杰,秦合伟,等.基于PI3K/Akt/m TOR信号通路调控巨噬细胞自噬探讨黄芪甲苷抗动脉粥样硬化的作用机制[J].中草药,2017,48(17):3575-3581.
[8]唐琪晶,陈素红,潘丹丹,等.白术精提物对代谢性高脂血症大鼠的药效及机制研究[J].中国中药杂志,2015,40(9):1803-1807.
[9]姜微哲,渠凯,朱海波.冬虫夏草提取物调血脂与抗氧化活性[J].中国实验方剂学杂志,2011,17(12):127-131.
[10]吴敬涛.桔梗皂苷的抗氧化及脂质调节作用研究[D].济南:山东师范大学,2011.
[11]毛跟年,张诗韵,付超,等.茯苓皮总三萜的降血脂活性研究[J].陕西科技大学学报(自然科学版),2015,33(3):130-134.
[12]张翔,江兴林,周利玲,等.大黄素对氧化应激所致动脉粥样硬化模型大鼠的干预研究[J].中医药导报,2016,22(21):27-29.
[13]黄志新,陶青,刘新通.半夏在动脉粥样硬化颈动脉血管内膜损伤中的修复作用研究[J].现代医院,2017,17(7):1053-1056.
[14]王浩然,曲彦明,于春江.川芎对Apo E-/-小鼠动脉粥样硬化抑制作用的研究[J].中华脑科疾病与康复杂志(电子版),2015,5(3):160-167.
[15]马艳春,周波,宋立群,等.地龙有效成分对糖尿病肾脏疾病患者血脂、脂质过氧化反应的影响[J].中国临床保健杂志,2012,15(1):53-54.
[2]邢玉瑞.中医浊毒概念问题探讨[J].中医杂志,2017,58(14):1171-1174.
[3]徐伟超,贾蕊,李欣,等.浊毒病机理论探微[J].新中医,2015,47(9):1-3.
[4]赵雯红,肖颖,王文举,等.以人体微生态学诠释浊毒理论的内涵[J].中医杂志,2018,59(3):185-190.
[5]李永朝.动脉粥样硬化发生机制的研究进展[J].临床合理用药,2018,11(2):174-175.
[6]刘含嫣,霍清萍.单核细胞趋化蛋白-1与动脉粥样硬化及中医药防治[J].中西医结合心脑血管病杂志,2011,9(2):218-221.
[7]张志鑫,李彦杰,秦合伟,等.基于PI3K/Akt/m TOR信号通路调控巨噬细胞自噬探讨黄芪甲苷抗动脉粥样硬化的作用机制[J].中草药,2017,48(17):3575-3581.
[8]唐琪晶,陈素红,潘丹丹,等.白术精提物对代谢性高脂血症大鼠的药效及机制研究[J].中国中药杂志,2015,40(9):1803-1807.
[9]姜微哲,渠凯,朱海波.冬虫夏草提取物调血脂与抗氧化活性[J].中国实验方剂学杂志,2011,17(12):127-131.
[10]吴敬涛.桔梗皂苷的抗氧化及脂质调节作用研究[D].济南:山东师范大学,2011.
[11]毛跟年,张诗韵,付超,等.茯苓皮总三萜的降血脂活性研究[J].陕西科技大学学报(自然科学版),2015,33(3):130-134.
[12]张翔,江兴林,周利玲,等.大黄素对氧化应激所致动脉粥样硬化模型大鼠的干预研究[J].中医药导报,2016,22(21):27-29.
[13]黄志新,陶青,刘新通.半夏在动脉粥样硬化颈动脉血管内膜损伤中的修复作用研究[J].现代医院,2017,17(7):1053-1056.
[14]王浩然,曲彦明,于春江.川芎对Apo E-/-小鼠动脉粥样硬化抑制作用的研究[J].中华脑科疾病与康复杂志(电子版),2015,5(3):160-167.
[15]马艳春,周波,宋立群,等.地龙有效成分对糖尿病肾脏疾病患者血脂、脂质过氧化反应的影响[J].中国临床保健杂志,2012,15(1):53-54.